MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

Phase 2
Completed
Conditions
Diabetic Neuropathies
Interventions
Drug: TAK-583
Drug: Placebo
First Posted Date
2008-09-26
Last Posted Date
2016-06-22
Lead Sponsor
Takeda
Target Recruit Count
338
Registration Number
NCT00760955

Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis

Phase 2
Completed
Conditions
Arthritis, Rheumatoid
Interventions
Drug: TAK-715 and methotrexate
Drug: Methotrexate
First Posted Date
2008-09-26
Last Posted Date
2010-06-11
Lead Sponsor
Takeda
Target Recruit Count
432
Registration Number
NCT00760864

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Phase 2
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: SYR-472
Drug: Placebo
Drug: Sitagliptin
First Posted Date
2008-09-26
Last Posted Date
2016-06-22
Lead Sponsor
Takeda
Target Recruit Count
386
Registration Number
NCT00760344

Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis

Phase 2
Completed
Conditions
Arthritis, Rheumatoid
Interventions
Drug: TAK-783 and methotrexate
Drug: Methotrexate
First Posted Date
2008-09-26
Last Posted Date
2010-06-11
Lead Sponsor
Takeda
Target Recruit Count
224
Registration Number
NCT00760968

Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.

Phase 3
Terminated
Conditions
Diabetes Mellitus
Interventions
Drug: TAK-559 and glyburide
Drug: Glyburide
First Posted Date
2008-09-25
Last Posted Date
2012-02-02
Lead Sponsor
Takeda
Target Recruit Count
447
Registration Number
NCT00759720

Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension

Phase 2
Completed
Conditions
Hypertension
Interventions
Drug: Azilsartan
Drug: Placebo
Drug: Olmesartan
First Posted Date
2008-09-25
Last Posted Date
2010-06-22
Lead Sponsor
Takeda
Target Recruit Count
555
Registration Number
NCT00759551

Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

Phase 2
Terminated
Conditions
Diabetic Neuropathies
Interventions
Drug: TAK-128
First Posted Date
2008-09-19
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
221
Registration Number
NCT00756041

Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia

Phase 2
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Drug: Ramelteon and gabapentin
Drug: Placebo
Drug: Ramelteon
Drug: Gabapentin
First Posted Date
2008-09-19
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
378
Registration Number
NCT00755508

Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.

Phase 2
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Placebo
Drug: Alogliptin
First Posted Date
2008-09-19
Last Posted Date
2012-02-03
Lead Sponsor
Takeda
Target Recruit Count
265
Registration Number
NCT00755846

Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia

Phase 2
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Drug: Ramelteon and doxepin
Drug: Placebo
Drug: Ramelteon
Drug: Doxepin
First Posted Date
2008-09-19
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
472
Registration Number
NCT00755495
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy